Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Total Current Liabilities (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Total Current Liabilities for 14 consecutive years, with $96.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 5.07% year-over-year to $96.1 million, compared with a TTM value of $96.1 million through Dec 2025, up 5.07%, and an annual FY2025 reading of $96.1 million, up 5.07% over the prior year.
  • Total Current Liabilities was $96.1 million for Q4 2025 at Heron Therapeutics, up from $89.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $258.6 million in Q2 2025 and bottomed at $71.1 million in Q4 2021.
  • Average Total Current Liabilities over 5 years is $94.7 million, with a median of $86.1 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities tumbled 30.68% in 2021, then surged 221.98% in 2025.
  • Year by year, Total Current Liabilities stood at $71.1 million in 2021, then increased by 15.9% to $82.4 million in 2022, then decreased by 3.24% to $79.7 million in 2023, then increased by 14.77% to $91.5 million in 2024, then grew by 5.07% to $96.1 million in 2025.
  • Business Quant data shows Total Current Liabilities for HRTX at $96.1 million in Q4 2025, $89.7 million in Q3 2025, and $258.6 million in Q2 2025.